In a recent news release, medical device company NeuroMetrix Inc, announces that it has received a 510(k) clearance for its SENSUS pain management device from the US Food and Drug Administration (FDA). The clearance allows NeuroMetrix to market the SENSUS device in the US market. The device is designed for use as a transcutaneous electrical nerve stimulator for the symptomatic relief and management of chronic intractable pain.

Shai N. Gozani, MD, PhD, NeuroMetrix president and CEO, adds that the, “FDA clearance keeps us on track to launch the SENSUS Pain Management System in the fourth quarter of 2012.” Gozani also articulates the company’s excitement about the potential adoption of the device, “by diabetes focused clinicians because a number of recent systematic literature reviews and meta-analyses have concluded that transcutaneous electrical nerve stimulation may be an effective and safe treatment for painful diabetic neuropathy,” Gozani notes.

Source: NeuroMetrix Inc